Pharmakologie der ADP-Rezeptoren auf humanen Thrombozyten

125. Sage, S.O., R. Reast, and T.J. Rink. 1990. ADP evokes biphasic Ca2+ influx in fura-2-loaded human
platelets. Evidence for Ca2+ entry regulated by the intracellular Ca2+ store. Biochem J
265:675-680.
126. Sandberg, M., E. Butt, C. Nolte, L. Fischer, M. Halbrugge, J. Beltman, T. Jahnsen, H.G. Genieser, B.
Jastorff, and U. Walter. 1991. Characterization of Sp-5,6-dichloro-1-beta-Dribofuranosylbenzimidazole-
3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent
and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells.
Biochem J 279 ( Pt 2):521-527.
127. Sanger, F., S. Nicklen, and A.R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors.
Proc Natl Acad Sci U S A 74:5463-5467.
128. Savage, B., J. Almus, and Z.M. Ruggeri. 1998. Specific synergy of multiple substrate-receptor
interactions in platelet thrombus formation under flow. Cell 94:657-666.
129. Savi, P., P. Beauverger, C. Labouret, M. Delfaud, V. Salel, M. Kaghad, and J.M. Herbert. 1998. Role
of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 422:291-295.
130. Savi, P., J. Combalbert, C. Gaich, M.C. Rouchon, J.P. Maffrand, Y. Berger, and J.M. Herbert. 1994.
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic
cytochrome P450-1A. Thromb Haemost 72:313-317.
131. Savi, P., J.M. Herbert, A.M. Pflieger, F. Dol, D. Delebassee, J. Combalbert, G. Defreyn, and J.P.
Maffrand. 1992. Importance of hepatic metabolism in the antiaggregating activity of the
thienopyridine clopidogrel. Biochem Pharmacol 44:527-532.
132. Savi, P., M.C. Laplace, J.P. Maffrand, and J.M. Herbert. 1994. Binding of [3H]-2-methylthio ADP to rat
platelets--effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772-777.
133. Savi, P., J.M. Pereillo, M.F. Uzabiaga, J. Combalbert, C. Picard, J.P. Maffrand, M. Pascal, and J.M.
Herbert. 2000. Identification and biological activity of the active metabolite of clopidogrel.
Thromb Haemost 84:891-896.
134. Savi, P., A.M. Pflieger, and J.M. Herbert. 1996. cAMP is not an important messenger for ADPinduced
platelet aggregation. Blood Coagul Fibrinolysis 7:249-252.
135. Scase, T.J., M.F. Heath, J.M. Allen, S.O. Sage, and R.J. Evans. 1998. Identification of a P2X1
purinoceptor expressed on human platelets. Biochem Biophys Res Commun 242:525-528.
136. Schachter, J.B., J.L. Boyer, Q. Li, R.A. Nicholas, and T.K. Harden. 1997. Fidelity in functional
coupling of the rat P2Y1 receptor to phospholipase C. Br J Pharmacol 122:1021-1024.
137. Schachter, J.B., Q. Li, J.L. Boyer, R.A. Nicholas, and T.K. Harden. 1996. Second messenger cascade
specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol
118:167-173.
138. Schror, K. 1995. Antiplatelet drugs. A comparative review. Drugs 50:7-28.
139. Schwarz, U.R., J. Geiger, U. Walter, and M. Eigenthaler. 1999. Flow cytometry analysis of
intracellular VASP phosphorylation for the assessment of activating and inhibitory signal
transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel
effects. Thromb Haemost 82:1145-1152.
140. Schwarz, U.R., U. Walter, and M. Eigenthaler. 2001. Taming platelets with cyclic nucleotides.
Biochem Pharmacol 62:1153-1161.
112